Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA profiles of primary breast cancer tumors of systematically untreated and lymph node negative patients

ABSTRACT: MicroRNA profiles of primary breast cancer tumors of systematically untreated and lymph node negative patients

PROVIDER: PRJNA521065 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MicroRNA profiles of primary breast cancer tumors of systematically untreated and lymph node negative patients

Project description:MicroRNA profiles of primary breast cancer tumors of systematically untreated and lymph node negative patients

2022-02-04 | GSE126125 | GEO

MicroRNA profiles of 110 primary breast cancer tumors of systemically untreated, lymph node negative and estrogen receptor positive patients

Project description:MicroRNA profiles of 110 primary breast cancer tumors of systematically untreated, lymph node negative and ER positive patients. Half of the patients developed metastasis while 55 patients remained metastasis-free. The miRCURY LNA microRNA array ready-to-spot probe-set was purchased from Exiqon. The set contains capture-probes for 1212 human, 1040 mouse and 679 rat miRNAs based on the miRBase version 16. Probes were spotted in triplets on CodeLink HD (SurModics) activated glass slides and post-processed according to the CodeLink protocol. SUBMITTER_CITATION: Ines Block, Mark Burton, Kristina P. Sørensen, Lars Andersen, Martin J. Larsen, Martin Bak, Søren Cold, Mads Thomassen, Qihua Tan, Torben A. Kruse. Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. Oncotarget 2018 Jan; 9:9030-9042. https://doi.org/10.18632/oncotarget.24088

2018-02-16 | GSE103161 | GEO

Lymph node myeloid cells

Project description:Lymph node myeloid cells

| PRJNA895429 | ENA

Transcriptomic survey of lymph node-positive vs. - negative ductal breast cancer

Project description:Lymph node involvement is a major prognostic variable in breast cancer. Whether the molecular mechanisms that drive breast cancer cells to colonize lymph nodes are shared with their capacity to form distant metastases is yet to be established. In a transcriptomic survey aimed at identifying molecular factors associated with lymph node involvement of ductal breast cancer, we found that luminal differentiation, assessed by the expression of estrogen receptor (ER) and/or progesterone receptor (PR) and GATA3, was only infrequently lost in node-positive primary tumors and in matched lymph node metastases. The transcription factor GATA3 critically determines luminal lineage specification of mammary epithelium and is widely considered a tumor and metastasis suppressor in breast cancer. Strong expression of GATA3 and ER in a majority of primary node-positive ductal breast cancer was corroborated by quantitative RT-PCR and immunohistochemistry in the initial sample set, and by immunohistochemistry in an additional set from 167 patients diagnosed of node-negative and positive primary infiltrating ductal breast cancer, including 102 samples from loco-regional lymph node metastases matched to their primary tumors, as well as 37 distant metastases. These observations suggest that loss of luminal differentiation is not a major factor driving the ability of breast cancer cells to colonize regional lymph nodes. The transcriptomic study comprises 16 samples from Lymph node metastasis from infiltrating ductal breast carcinoma, 18 samples from Primary node-positive infiltrating ductal,7 samples from Primary node-negative infiltrating ductal and 3 samples from Unaffected lymph node were included. Their RNA was isolated and prepared for hybridization to human Affymetrix GeneChip arrays.

2013-03-05 | E-GEOD-44408 | biostudies-arrayexpress

Transcriptomic survey of lymph node-positive vs. - negative ductal breast cancer

Project description: Lymph node involvement is a major prognostic variable in breast cancer. Whether the molecular mechanisms that drive breast cancer cells to colonize lymph nodes are shared with their capacity to form distant metastases is yet to be established. In a transcriptomic survey aimed at identifying molecular factors associated with lymph node involvement of ductal breast cancer, we found that luminal differentiation, assessed by the expression of estrogen receptor (ER) and/or progesterone receptor (PR) and GATA3, was only infrequently lost in node-positive primary tumors and in matched lymph node metastases. The transcription factor GATA3 critically determines luminal lineage specification of mammary epithelium and is widely considered a tumor and metastasis suppressor in breast cancer. Strong expression of GATA3 and ER in a majority of primary node-positive ductal breast cancer was corroborated by quantitative RT-PCR and immunohistochemistry in the initial sample set, and by immunohistochemistry in an additional set from 167 patients diagnosed of node-negative and –positive primary infiltrating ductal breast cancer, including 102 samples from loco-regional lymph node metastases matched to their primary tumors, as well as 37 distant metastases. These observations suggest that loss of luminal differentiation is not a major factor driving the ability of breast cancer cells to colonize regional lymph nodes.

2013-03-05 | GSE44408 | GEO

Comparison of lymph node negative (N0) and lymph node metastasis (N+) head and neck squamous-cell carcinomas (HNSCC)

Project description:A classifier was build on 82 training samples to differentiate between lymph node negative (N0) and lymph node metastasis (N+) head and neck squamous-cell carcinomas (HNSCC). The 102 predictor genes that resulted from this classifier where then validated against a independent validation set.

2005-01-09 | E-UMCU-11 | biostudies-arrayexpress

Comparative analysis of mRNA expression in untreated lymph node stroma cells and upon treatment with exosomes derived from ASMLwt, ASML cd44v knockdown cells.

2011-12-28 | GSE34737 | GEO

Expression data from 4T1 subclones derived from mammary fat pad tumors (MFP), axillary lymph node tumors (AxLN), and axillary lymph node-derived lung metastases (AxLN-LuM)

Project description:Expression data from 4T1 subclones derived from mammary fat pad tumors (MFP), axillary lymph node tumors (AxLN), and axillary lymph node-derived lung metastases (AxLN-LuM). In parallel, expression data, in the same subclones, of tail vein-derived (TV) lung metastases. The mechanism of how lymph node metastases seed distant metastases is unknown. We used the 4T1 breast cancer cell line, which is an immune competent model of triple negative breast cancer and spontaneously metastasizes in balb/c mice. 4T1-GFP/fLuc cells were injected into MFP to form tumors and 4T1-mCherry/rLuc cells were injected into axillary lymph nodes to form tumors and then allowed to metastasize to lung. TV cells were allowed to metastasize in the lung. Cells were harvested at different time intervals after the injection. Tumors were extracted, dissociated, and then expanded in vitro to obtain MFP, AxLN, AxLN-LuM and TV-LuM subclones isolated after different time lags with respect to the injection.

2019-08-20 | GSE136031 | GEO

Comparative analysis of mRNA expression in untreated lymph node stroma cells and upon treatment with exosomes derived from ASMLwt, ASML cd44v knockdown cells.

Project description:Comparison of total RNA isolated from ASML and ASML CD44v knockdown exosomes; and RNA from untreated B12 lymph node stroma cells vs. cells treated for 24h with ASML wt or ASML CD44v kd exosomes The array consists of 12 samples. Samples 1-3 consist of total RNA from exosomes derived from ASML cells; samples 4-6 : total RNA from exosomes derived from ASML CD44v knockdown cell; samples 7,8 are total RNA from untreated B12 lymph node stroma cells; samples 9,10 are RNA from B12 cells treated for 24h with ASML wt exosomes and samples 11, 12 are RNA from B12 cells treated with ASML CD44v kd exosomes

2011-12-28 | E-GEOD-34737 | biostudies-arrayexpress

The Proteomic Fingerprint of Prostate Cancer in Primary Tumors and Recurrent Lymph Node Metastases

Project description:We performed a quantitative proteome comparison on formalin-fixed paraffin embedded (FFPE) tissue of metastasized and non-metastasized primary prostate cancer (PCa) and on recurrent lymph node metastases. Comparing these three sample groups, we aimed to identify proteins, that might potentially promote/supress tumor progression or metastasis formation. Proteins were quantified label-free. Proteins with interesting biological functions were followed-up by immunohistochemistry.

2017-12-19 | PXD005833 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data